A BiTE antibody binds both CD3+ cytotoxic T cells and a target antigen to bring the two cells into proximity and thus triggers T cells to kill tumor cells via perforin-mediated apoptosis.166 Blinatumomab is a CD19/CD3 BiTE that shows remarkable anti-lymphoma activity both in vitro and in vivo.167,168 In a phase 1 dose-escalation study (NCT00274742) in patients with relapsed or refractory NHLs, 60 μg/m2/day was established as the maximum tolerated dose, with 22% of patients experiencing grade 3 neurologic events. This evidence concerns the gene CD19 and neoplasm.